Inhibrx Biosciences Reports Positive Interim Results for INBRX-106 Phase 2
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2026
0mins
Inhibrx Biosciences announced positive interim results from the randomized, first-line Phase 2 portion of the HexAgon study. The trial evaluated the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab - the combination arm - versus pembrolizumab monotherapy - the control arm - in first-line patients with treatment-naive, PD-L1 positive metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma, or HNSCC. 11 out of 25 patients in the INBRX-106 combination arm achieved a confirmed objective response, compared with 6 out of 28 patients in the control arm. This represents a 22.6% absolute increase in confirmed responses. Three complete responses were observed in the INBRX-106 combination arm. These clinical findings were supported by pharmacodynamic data, which showed up to a 15-fold increase in peripheral CD8+ and CD4+ T-cell proliferation and up to a four-fold increase in activation in INBRX-106 combination-treated patients compared with up to 2.5-fold and 1.5-fold increases, respectively, in those receiving pembrolizumab alone. The combination of INBRX-106 and pembrolizumab was generally manageable, with a safety profile consistent with the addition of an active immunostimulatory agent to checkpoint blockade. The progression-free survival data from the Phase 2 portion of the HexAgon study are expected to become available in Q4. The company plans to begin the Phase 3 portion of the HexAgon study during Q3. In addition, the company is beginning to plan for expansion into the front-line metastatic NSCLC setting, with studies expected to begin in 2027.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INBX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INBX
About INBX
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is an engineered tetravalent single domain antibody (sdAb)-based therapeutic candidate that agonizes DR5 to induce tumor selective programmed cell death. INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40 that provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death. INBRX-106 in Combination with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Accepts Inhibrx Biosciences' BLA for Ozekibart Review
- FDA Review Progress: The US FDA has accepted Inhibrx Biosciences' Biologics License Application (BLA) for ozekibart, aimed at treating unresectable or metastatic conventional chondrosarcoma, marking a significant advancement for the company in the rare bone cancer treatment space.
- Key Timeline: The action date for this application is set for April 14, 2027, and if approved, it will address the current lack of FDA-approved therapies in the market, potentially providing new treatment options for patients.
- Clinical Study Support: The BLA is supported by data from the ChonDRAgon study, which demonstrated a statistically significant median progression-free survival for patients treated with ozekibart compared to those receiving placebo, further validating the drug's clinical efficacy.
- Drug Mechanism: Ozekibart is considered a tetravalent death receptor 5 (DR5) agonist antibody, and its unique mechanism of action may offer new hope for treating this rare cancer, enhancing Inhibrx's competitiveness in the biopharmaceutical sector.
See More
Inhibrx Files Biologics License Application for Ozekibart
- FDA Filing Acceptance: Inhibrx Biosciences announced that its Biologics License Application for ozekibart has been accepted by the FDA, targeting treatment for unresectable or metastatic conventional chondrosarcoma, a rare cancer, which, if approved, would mark the company's first commercial product and hold significant market potential.
- PDUFA Goal Date: The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027, indicating that a decision on the drug's approval will be made by this date, potentially offering new treatment options for patients if successful.
- Clinical Trial Results: Ozekibart demonstrated strong efficacy in the ChonDRAgon study, achieving a statistically significant median progression-free survival of 5.52 months compared to 2.66 months for placebo, with a 52% reduction in the risk of disease progression or death, providing robust support for the drug's effectiveness.
- Positive Market Reaction: Currently, INBX shares are up 1.40% to $93.49 on Nasdaq, reflecting market optimism regarding the potential success of the drug, which could drive future growth and investor confidence for the company.
See More
Inhibrx's BLA for Ozekibart Accepted by FDA
- FDA Filing Acceptance: Inhibrx announced that the FDA has accepted its Biologics License Application (BLA) for ozekibart (INBRX-109) aimed at treating unresectable or metastatic chondrosarcoma, marking a significant milestone for the company with a review goal date set for April 14, 2027.
- Clinical Trial Results: Ozekibart demonstrated significant efficacy in the ChonDRAgon study, achieving a median progression-free survival (PFS) of 5.52 months compared to 2.66 months for placebo, resulting in a 52% reduction in the risk of disease progression or death, highlighting its potential in treating chondrosarcoma.
- Market Potential: If approved, ozekibart will become Inhibrx's first commercial product and the first systemic therapy for unresectable or metastatic chondrosarcoma, addressing a critical unmet need in the market and offering hope to patients.
- Safety Profile: Ozekibart exhibited a manageable safety profile, with treatment-related hepatic adverse events occurring at a rate of only 11.8%, thanks to stringent patient selection and monitoring, indicating its feasibility for clinical use.
See More
Inhibrx's BLA for Ozekibart Accepted by FDA, Paving Way for First Treatment of Chondrosarcoma
- FDA Filing Acceptance: Inhibrx's Biologics License Application (BLA) for ozekibart has been accepted by the FDA, with a PDUFA goal date set for April 14, 2027, and if approved, it will be the first FDA-approved treatment for unresectable or metastatic chondrosarcoma, marking a significant milestone for the company in the biopharmaceutical sector.
- Clinical Trial Results: The ChonDRAgon study demonstrated ozekibart's efficacy, with a median progression-free survival (PFS) of 5.52 months in the treatment group compared to 2.66 months for placebo, achieving a 52% reduction in risk of disease progression (HR 0.479), providing new hope for patients.
- Significant Market Potential: If approved, ozekibart will become Inhibrx's first commercial product and the first systemic therapeutic option for this rare cancer, expected to fill a market gap and meet urgent patient needs.
- Manageable Safety Profile: Ozekibart has a manageable safety profile, with treatment-related adverse events occurring at a rate of 11.8%, predominantly grade 1 or 2, indicating its acceptability in clinical use and potential competitiveness in the market.
See More
Inhibrx Biosciences Reports Q1 Financial Results
- Financial Performance: Inhibrx Biosciences reported a Q1 GAAP EPS of -$2.15, indicating challenges in profitability, although market sentiment remains optimistic about the company's future potential.
- Cash Position: As of March 31, 2026, the company had cash and cash equivalents of $161.7 million, an increase from $124.2 million as of December 31, 2025, reflecting improved cash management practices.
- Funding Progress: The increase in cash balance is primarily due to gross proceeds of $75 million received in March 2026 from the First Amendment to the Loan and Security Agreement with Oxford Finance LLC, providing essential funding for future R&D initiatives.
- Market Reaction: Despite the reported losses, Inhibrx's stock surged due to anticipation of upcoming interim mid-stage data for its head and neck cancer asset, demonstrating investor confidence in the company's strategic direction.
See More
Inhibrx Biosciences Shares Rise 4% After Phase 2 Trial Announcement
- Clinical Trial Progress: Inhibrx Biosciences announced it will release interim results on May 11 from a phase 2 trial of INBRX-106 for first-line head and neck squamous cell carcinoma, which is expected to positively impact the company's stock price.
- Combination Therapy Study: The data will compare the efficacy of INBRX-106 in combination with Merck's Keytruda (pembrolizumab) versus Keytruda alone, and positive results could enhance the market competitiveness of INHBRX-106.
- Innovative Drug Mechanism: INBRX-106 is a hexavalent agonist designed to achieve high-order receptor clustering for effective T-cell activation and survival, potentially overcoming the limitations of traditional bivalent antibody approaches.
- Increased Market Attention: As the release of clinical data approaches, Inhibrx's stock is gaining market attention, with analysts maintaining an optimistic outlook, which may attract more investor interest.
See More
FDA Accepts Inhibrx Biosciences' BLA for Ozekibart Review
- FDA Review Progress: The US FDA has accepted Inhibrx Biosciences' Biologics License Application (BLA) for ozekibart, aimed at treating unresectable or metastatic conventional chondrosarcoma, marking a significant advancement for the company in the rare bone cancer treatment space.
- Key Timeline: The action date for this application is set for April 14, 2027, and if approved, it will address the current lack of FDA-approved therapies in the market, potentially providing new treatment options for patients.
- Clinical Study Support: The BLA is supported by data from the ChonDRAgon study, which demonstrated a statistically significant median progression-free survival for patients treated with ozekibart compared to those receiving placebo, further validating the drug's clinical efficacy.
- Drug Mechanism: Ozekibart is considered a tetravalent death receptor 5 (DR5) agonist antibody, and its unique mechanism of action may offer new hope for treating this rare cancer, enhancing Inhibrx's competitiveness in the biopharmaceutical sector.
See More
Inhibrx Files Biologics License Application for Ozekibart
- FDA Filing Acceptance: Inhibrx Biosciences announced that its Biologics License Application for ozekibart has been accepted by the FDA, targeting treatment for unresectable or metastatic conventional chondrosarcoma, a rare cancer, which, if approved, would mark the company's first commercial product and hold significant market potential.
- PDUFA Goal Date: The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027, indicating that a decision on the drug's approval will be made by this date, potentially offering new treatment options for patients if successful.
- Clinical Trial Results: Ozekibart demonstrated strong efficacy in the ChonDRAgon study, achieving a statistically significant median progression-free survival of 5.52 months compared to 2.66 months for placebo, with a 52% reduction in the risk of disease progression or death, providing robust support for the drug's effectiveness.
- Positive Market Reaction: Currently, INBX shares are up 1.40% to $93.49 on Nasdaq, reflecting market optimism regarding the potential success of the drug, which could drive future growth and investor confidence for the company.
See More
Inhibrx's BLA for Ozekibart Accepted by FDA
- FDA Filing Acceptance: Inhibrx announced that the FDA has accepted its Biologics License Application (BLA) for ozekibart (INBRX-109) aimed at treating unresectable or metastatic chondrosarcoma, marking a significant milestone for the company with a review goal date set for April 14, 2027.
- Clinical Trial Results: Ozekibart demonstrated significant efficacy in the ChonDRAgon study, achieving a median progression-free survival (PFS) of 5.52 months compared to 2.66 months for placebo, resulting in a 52% reduction in the risk of disease progression or death, highlighting its potential in treating chondrosarcoma.
- Market Potential: If approved, ozekibart will become Inhibrx's first commercial product and the first systemic therapy for unresectable or metastatic chondrosarcoma, addressing a critical unmet need in the market and offering hope to patients.
- Safety Profile: Ozekibart exhibited a manageable safety profile, with treatment-related hepatic adverse events occurring at a rate of only 11.8%, thanks to stringent patient selection and monitoring, indicating its feasibility for clinical use.
See More
Inhibrx's BLA for Ozekibart Accepted by FDA, Paving Way for First Treatment of Chondrosarcoma
- FDA Filing Acceptance: Inhibrx's Biologics License Application (BLA) for ozekibart has been accepted by the FDA, with a PDUFA goal date set for April 14, 2027, and if approved, it will be the first FDA-approved treatment for unresectable or metastatic chondrosarcoma, marking a significant milestone for the company in the biopharmaceutical sector.
- Clinical Trial Results: The ChonDRAgon study demonstrated ozekibart's efficacy, with a median progression-free survival (PFS) of 5.52 months in the treatment group compared to 2.66 months for placebo, achieving a 52% reduction in risk of disease progression (HR 0.479), providing new hope for patients.
- Significant Market Potential: If approved, ozekibart will become Inhibrx's first commercial product and the first systemic therapeutic option for this rare cancer, expected to fill a market gap and meet urgent patient needs.
- Manageable Safety Profile: Ozekibart has a manageable safety profile, with treatment-related adverse events occurring at a rate of 11.8%, predominantly grade 1 or 2, indicating its acceptability in clinical use and potential competitiveness in the market.
See More
Inhibrx Biosciences Reports Q1 Financial Results
- Financial Performance: Inhibrx Biosciences reported a Q1 GAAP EPS of -$2.15, indicating challenges in profitability, although market sentiment remains optimistic about the company's future potential.
- Cash Position: As of March 31, 2026, the company had cash and cash equivalents of $161.7 million, an increase from $124.2 million as of December 31, 2025, reflecting improved cash management practices.
- Funding Progress: The increase in cash balance is primarily due to gross proceeds of $75 million received in March 2026 from the First Amendment to the Loan and Security Agreement with Oxford Finance LLC, providing essential funding for future R&D initiatives.
- Market Reaction: Despite the reported losses, Inhibrx's stock surged due to anticipation of upcoming interim mid-stage data for its head and neck cancer asset, demonstrating investor confidence in the company's strategic direction.
See More
Inhibrx Biosciences Shares Rise 4% After Phase 2 Trial Announcement
- Clinical Trial Progress: Inhibrx Biosciences announced it will release interim results on May 11 from a phase 2 trial of INBRX-106 for first-line head and neck squamous cell carcinoma, which is expected to positively impact the company's stock price.
- Combination Therapy Study: The data will compare the efficacy of INBRX-106 in combination with Merck's Keytruda (pembrolizumab) versus Keytruda alone, and positive results could enhance the market competitiveness of INHBRX-106.
- Innovative Drug Mechanism: INBRX-106 is a hexavalent agonist designed to achieve high-order receptor clustering for effective T-cell activation and survival, potentially overcoming the limitations of traditional bivalent antibody approaches.
- Increased Market Attention: As the release of clinical data approaches, Inhibrx's stock is gaining market attention, with analysts maintaining an optimistic outlook, which may attract more investor interest.
See More
